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ronedarone Is Superior to Placebo
he Case for Optimism
read with interest the study by Piccini et al. (1) that evaluated
ronedarone for treating atrial fibrillation (AF). I agree with the
rimary conclusion that amiodarone is more effective than drone-
arone for maintenance of sinus rhythm, as would be expected on
he basis of the DIONYSOS (Efficacy and Safety of Dronedarone
ersus Amiodarone for the Maintenance of Sinus Rhythm in
atients with Atrial Fibrillation) trial (2). However, I have concern
bout the dronedarone data that might have mistakenly led to an
verly negative appraisal of its effect.
In Figure 2A of the paper (1), the authors present an odds ratio
lot for EURIDIS (EURopean trial In atrial fibrillation or flutter
atients receiving Dronedarone for the maIntenance of Sinus
hythm) and ADONIS (American-Australasian trial with Drone-
arONe In atrial fibrillation or flutter patients for the maintenance
f Sinus rhythm) (3). The data as presented suggest that placebo
ad efficacy comparable to dronedarone in these studies, which
irectly contradicts the studies’ conclusions. The answer to this
nconsistency lies in the supporting data to the right of the odds
atio plot. For EURIDIS, the denominators of 411 and 201
atients/treatment arm come from the second line of Table 2 of
he trial’s publication (3). The numerators are supposed to repre-
ent the number of patients with recurrent AF and are also taken
rom Table 2, 5th line of data (1).
These numbers do not make sense as representing the number
f patients with recurrent AF at 1 year. They would correspond to
4.7% (307 of 411) and 73.6% (148 of 201) with recurrent AF at
year for dronedarone and placebo, respectively, and thus would
how no difference between the 2 treatments. The actual reported
ecurrence rates of AF at 1 year (Table 2, line 3 [1]) are 67.1% and
7.5% for dronedarone and placebo, respectively. Instead, I believe
hat the number of patients presented in line 5 of the table likely
epresents the denominator for the analysis that follows, much like
he number of patients in line 2 also is a denominator, and absolute
umbers of patients with recurrent AF are not specified, favoring
resenting these data as percentages (1). It is also possible that the eumbers in line 5 present some other subselection of the total
atient population, but it is inconsistent with the results of
URIDIS to assume that they represent the number of patients
ith recurrent AF. The same number sources are used for
DONIS. This artificially makes dronedarone seem the same as
lacebo in terms of AF recurrence rate at 1 year, a finding that
ignificantly differs from the data in Table 2 and the Kaplan-Meier
lots in Figure 2 (3).
While awaiting clarification from the authors of EURIDIS and
DONIS, there seems to be an error here that creates an overly
egative conclusion as to the effect of dronedarone. After all,
ronedarone has already been demonstrated in several studies to be
uperior to placebo (3,4) and not equal to it, as is suggested by the
rticle by Piccini et al. (1).
Jonas A. Cooper, MD, MPH
Washington University School of Medicine
epartment of Medicine
ardiovascular Division
60 South Euclid Avenue, Box 8086
t. Louis, Missouri 63110
-mail: jonas_cooper@yahoo.com
doi:10.1016/j.jacc.2009.11.045
EFERENCES
. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong
DF. Comparative efficacy of dronedarone and amiodarone for the
maintenance of sinus rhythm in patients with atrial fibrillation. J Am
Coll Cardiol 2009;54:1089–95.
. Sanofi-Aventis Press Release. DIONYSOS study results showed the
respective profiles of dronedarone and amiodarone. December 23,
2008. Available at: http://en.sanofi-aventis.com/binaries/20081223_
dionysos_fe_en_en_tcm28-23624.pdf. Accessed October 6, 2009.
. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance
of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357:
987–99.
. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser
SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging
study. Eur Heart J 2003;24:1481–7.
eply
e appreciate the opinions of Dr. Lewalter regarding our meth-
dology (1), particularly the use of intention-to-treat populations.
he meta-analysis was constructed with conservative assumptions
o reduce the risk of type I error. From this perspective, when
stimating potential differences among treatments, biases that
ake the treatments seem more similar (including crossovers or
ailure to receive treatment) are conservative assumptions.
ntention-to-treat provides the best pragmatic estimate of a given
herapeutic strategy (in this case, therapy with dronedarone vs.
miodarone) (2). Often disagreement arises over the exact defini-
ion of intention-to-treat in an individual trial. In our meta-
nalysis we attempted to include patients in the denominator
ccording to treatment allocation at the time of randomization.
Although the primary end point in EURIDIS (EURopean trial In
trial fibrillation or flutter patients receiving Dronedarone for the
aIntenance of Sinus rhythm) and ADONIS (American-
ustralasian trial with DronedarONe In atrial fibrillation or flutter
atients for the maintenance of Sinus rhythm) (3) was the time to
ecurrence of atrial fibrillation (AF), in our analysis the primary
fficacy end point was recurrent AF at follow-up. This approach was
